Mantle Cell Lymphoma

Novel induction regimens in transplantation for mantle cell lymphoma – pro

Lay Summary: Stem cell transplantation is standard of care for mantle cell lymphoma. Mantle cell lymphoma is a fairly recently identified subtype of non-Hodgkin's lymphoma. Regarded as a low-grade tumour in previous classifications, it has a median survival of only 36 months and is incurable by current treatment approaches. Widespread disease is usually present at diagnosis involving lymph nodes, spleen, bone marrow and extranodal sites such as the

Read more
Thalidomide or Lenalidomide and Rituximab for Mantle Cell Lymphoma – pro

Thalidomide, lenalidomide and rituximab have no direct effect on MCL cells. However, both indirectly affect peripheral blood mononuclear cell-mediated cytotoxicity,  and rituximab induces both complement-dependent and antibody-dependent cellular cytotoxicity (ADCC) against MCL cells. Rituximab-induced ADCC is enhanced by lenalidomide and thalidomide. In a 2004 series, thirteen patients of sixteen enrolled (81%) experienced an objective response,

Read more

Fatal error: Call to undefined function fw_blog_pagination() in /home/content/43/9379243/html/wp-content/themes/wisdom/blog_category.php on line 39